Summary of risk management plan for Mirtazapin Devatis 15 mg, 30mg and 45mg, Filmtabletten (Mirtazapine)

This is a summary of the risk management plan (RMP) for Mirtazapin Devatis 15 mg, Filmtabletten Mirtazapin Devatis 30 mg, Filmtabletten and Mirtazapin Devatis 45 mg, Filmtabletten. The RMP details important risks of Mirtazapin Devatis 15 mg, Filmtabletten Mirtazapin Devatis 30 mg, Filmtabletten and Mirtazapin Devatis 45 mg, Filmtabletten, how these risks can be minimised, and how more information will be obtained about Mirtazapin Devatis 15 mg, Filmtabletten Mirtazapin Devatis 30 mg, Filmtabletten and Mirtazapin Devatis 45 mg, Filmtabletten's risks and uncertainties (missing information).

Mirtazapin Devatis 15 mg, Filmtabletten Mirtazapin Devatis 30 mg, Filmtabletten and Mirtazapin Devatis 45 mg, Filmtabletten 's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Mirtazapin Devatis 15 mg, Filmtabletten Mirtazapin Devatis 30 mg, Filmtabletten and Mirtazapin Devatis 45 mg, Filmtabletten should be used.

Important new concerns or changes to the current ones will be included in updates of Mirtazapin Devatis 15 mg, Filmtabletten Mirtazapin Devatis 30 mg, Filmtabletten and Mirtazapin Devatis 45 mg, Filmtabletten 's RMP.

I. The medicine and what it is used for

Mirtazapin Devatis 15 mg, Filmtabletten Mirtazapin Devatis 30 mg, Filmtabletten and Mirtazapin Devatis 45 mg, Filmtabletten are authorised for the treatment of episodes of major depression in adults.

It contains Mirtazapine as the active substance, and it is given by oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Mirtazapin Devatis 15 mg, Filmtabletten Mirtazapin Devatis 30 mg, Filmtabletten and Mirtazapin Devatis 45 mg, Filmtabletten, together with measures to minimise such risks and the proposed studies for learning more about Mirtazapin Devatis 15 mg, Filmtabletten Mirtazapin Devatis 30 mg, Filmtabletten and Mirtazapin Devatis 45 mg, Filmtabletten 's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;

- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Mirtazapin Devatis 15 mg, Filmtabletten Mirtazapin Devatis 30 mg, Filmtabletten and Mirtazapin Devatis 45 mg, Filmtabletten are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Mirtazapin Devatis 15 mg, Filmtabletten Mirtazapin Devatis 30 mg, Filmtabletten and Mirtazapin Devatis 45 mg, Filmtabletten. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	QT prolongation and/or ventricular arrhythmia (e.g. Torsades de Pointes)
Important potential risks	None
Missing information	None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Mirtazapin Devatis 15 mg, Filmtabletten Mirtazapin Devatis 30 mg, Filmtabletten and Mirtazapin Devatis 45 mg, Filmtabletten.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Mirtazapin Devatis 15 mg, Filmtabletten Mirtazapin Devatis 30 mg, Filmtabletten and Mirtazapin Devatis 45 mg, Filmtabletten.